Abstract：
UNASSIGNED: Osteoarthritis (OA) is a chronic and degenerative joint disease that remains a great challenge in treatment due to the lack of effective therapies. 4-octyl itaconate (4-OI) is a novel and potent modulator of inflammation for the treatment of inflammatory disease. However, the clinical usage of 4-OI is limited due to its poor solubility and low bioavailability. As a promising drug delivery strategy, injectable hydrogels offers an effective approach to address these limitations of 4-OI.
UNASSIGNED: The aim of the study was to verify that the composite 4-OI/SA hydrogels could achieve a controlled release of 4-OI and reduce damage to articular cartilage in the group of osteoarthritic rats treated with the system.
UNASSIGNED: In this study, an injectable composite hydrogel containing sodium alginate (SA) and 4-octyl itaconate (4-OI) has been developed for continuous intra-articular administration in the treatment of OA.
UNASSIGNED: After intra-articular injection in arthritic rats, the as-prepared 4-OI/SA hydrogel containing of 62.5 μM 4-OI effectively significantly reduced the expression of TNF-α, IL-1β, IL-6 and MMP3 in the ankle fluid. Most importantly, the as-prepared 4-OI/SA hydrogel system restored the morphological parameters of the ankle joints close to normal.
UNASSIGNED: 4-OI/SA hydrogel shows a good anti-inflammatory activity and reverse cartilage disruption, which provide a new strategy for the clinical treatment of OA.
UNASSIGNED: The aim of the study was to verify that the composite 4-OI/SA hydrogels could achieve a controlled release of 4-OI and reduce damage to articular cartilage in the group of osteoarthritic rats treated with the system.
UNASSIGNED: In this study, an injectable composite hydrogel containing sodium alginate (SA) and 4-octyl itaconate (4-OI) has been developed for continuous intra-articular administration in the treatment of OA.
UNASSIGNED: After intra-articular injection in arthritic rats, the as-prepared 4-OI/SA hydrogel containing of 62.5 μM 4-OI effectively significantly reduced the expression of TNF-α, IL-1β, IL-6 and MMP3 in the ankle fluid. Most importantly, the as-prepared 4-OI/SA hydrogel system restored the morphological parameters of the ankle joints close to normal.
UNASSIGNED: 4-OI/SA hydrogel shows a good anti-inflammatory activity and reverse cartilage disruption, which provide a new strategy for the clinical treatment of OA.
摘要：
■骨关节炎（OA）是一种慢性和退行性关节疾病，由于缺乏有效的疗法，在治疗中仍然是一个巨大的挑战。4-辛基衣康酸(4-OI)是用于治疗炎性疾病的新型和有效的炎症调节剂。然而,4-OI的临床应用由于其溶解性差和生物利用度低而受到限制。作为一种有前途的药物输送策略，可注射水凝胶提供了解决4-OI的这些限制的有效方法。
■该研究的目的是验证复合4-OI/SA水凝胶可以实现4-OI的受控释放并减少对骨关节炎治疗组的关节软骨的损伤。系统。
■在这项研究中，已经开发了含有藻酸钠(SA)和4-辛基衣康酸(4-OI)的可注射复合水凝胶,用于治疗OA的连续关节内给药。
■关节炎大鼠关节内注射后，制备的含有62.5μM4-OI的4-OI/SA水凝胶能显著降低TNF-α的表达,IL-1β,踝部液中IL-6和MMP3。最重要的是,制备的4-OI/SA水凝胶系统使踝关节的形态参数恢复正常。
■4-OI/SA水凝胶显示出良好的抗炎活性和逆转软骨破坏，为OA的临床治疗提供了新的策略。
■该研究的目的是验证复合4-OI/SA水凝胶可以实现4-OI的受控释放并减少对骨关节炎治疗组的关节软骨的损伤。系统。
■在这项研究中，已经开发了含有藻酸钠(SA)和4-辛基衣康酸(4-OI)的可注射复合水凝胶,用于治疗OA的连续关节内给药。
■关节炎大鼠关节内注射后，制备的含有62.5μM4-OI的4-OI/SA水凝胶能显著降低TNF-α的表达,IL-1β,踝部液中IL-6和MMP3。最重要的是,制备的4-OI/SA水凝胶系统使踝关节的形态参数恢复正常。
■4-OI/SA水凝胶显示出良好的抗炎活性和逆转软骨破坏，为OA的临床治疗提供了新的策略。
